Multivalent pneumococcal polysaccharide-protein conjugate vaccine
By developing a 24-valent pneumococcal polysaccharide-protein conjugation vaccine, using CDAP activation and size exclusion chromatography and other technologies, the problem of poor effect of existing vaccines in serotype coverage and immune response has been solved, and stronger immune protection capabilities have been achieved .
Patent Information
- Application Number
- CN201980082847.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-10-12
- Filing Date
- 2019-10-11
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2039-10-11
AI Technical Summary
The existing pneumococcal vaccine has limited serotype coverage in some areas, especially in infants and young children who respond poorly to non-conjugated pneumococcal polysaccharide vaccines, and the immune response effect of the existing polyvalent pneumococcal conjugated vaccines is not ideal.
Develop a 24-valent pneumococcal polysaccharide-protein conjugation vaccine containing 24 different serotypes of Streptococcus pneumonia capsular polysaccharides conjugated to carrier proteins (such as CRM197, PsaA, tetanus toxoids, etc.), and is activated and sized by CDAP Exclude chromatography and other technologies to purify and formulate efficient vaccine compositions.
It provides a better immune response effect than the original multivalent pneumococcal vaccine and the existing pneumococcal conjugated vaccine, significantly improving the protection ability of multiple serotypes.
Smart Images

Figure BDA0003114448960000271 
Figure BDA0003114448960000272 
Figure BDA0003114448960000273
Abstract
Description
Technical Field
[0001] The present invention relates to a multivalent pneumococcal polysaccharide-protein conjugate vaccine composition comprising pneumococcal capsular polysaccharide of one or more serotypes of Streptococcus pneumoniae conjugated to one or more carrier proteins. Background Art
[0002] Streptococcus pneumoniae ("pneumococcus") is a gram-positive bacterium that can cause invasive diseases such as pneumonia, bacteremia, and meningitis, as well as diseases associated with colonization, such as acute otitis media (e.g., colonization in the middle ear). These pneumococcal diseases cause morbidity and mortality, especially in people younger than 24 months and older than 60 years of age. In the United States, the incidence of pneumococcal pneumonia in people older than 60 years is approximately 3-8 per 100,000 people. In 20% of cases, pneumococcal pneumonia leads to bacteremia and meningitis, and despite antibiotic treatment, the overall mortality rate approaches 30%.
[0003] Pneumococcal vaccines can be used to prevent infection. Current vaccines include multivalent pneumococcal polysaccharide vaccines (including pneumococcal polysaccharides from two or more serotypes) and pneumococcal conjugate vaccines. It is known that the protective efficacy of pneumococcal polysaccharide vaccines is related to the concentration of antibodies produced against the capsular polysaccharide. Pneumococcal cells are coated with polysaccharides, resulting in more than 90 different pneumococcal serotypes. The capsule is the main virulence determinant of pneumococci, which not only protects the intracellular surface from complement-mediated cytolysis, but also has poor immunogenicity.
[0004] Merck 23 is a multivalent pneumococcal polysaccharide vaccine containing unconjugated capsular polysaccharides of 23 pneumococcal serotypes, including serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F. 23. The multivalent pneumococcal polysaccharide vaccines licensed to date have proven to be valuable in preventing pneumococcal disease in adults, especially the elderly and high-risk groups. However, infants and young children do not respond well to these non-conjugated pneumococcal polysaccharide vaccines.
[0005] It is a pneumococcal polysaccharide-protein conjugate vaccine that contains the seven most commonly isolated polysaccharide serotypes (e.g., 197 Conjugated 4, 6B, 9V, 14, 18C, 19F and 23F). Since the United States began using it in 2000 Since then, invasive pneumococcal disease (IPD) in children has decreased significantly. In some parts of the world, serotype coverage is limited, so a 13-valent conjugate vaccine has been developed and licensed Contains 13 CRM 197 Conjugated serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
[0006] It is a pneumococcal vaccine that includes 10 polysaccharides serotypes 1, 4, 5, 6B, 7F, 9V, 14, 23F conjugated to protein D (PD), serotype 18C conjugated to tetanus toxoid (TT) and serotype 19F conjugated to diphtheria toxoid (DT). Each serotype polysaccharide is coupled using 1-cyano-4-dimethylaminopyridine tetrafluoroborate (CDAP) under controlled pH.
[0007] U.S. Patent No. 5,360,897 discloses a pneumococcal vaccine wherein an immunogenic conjugate comprises a reductive amination product of an intact capsular polymer of the bacterial pathogen Streptococcus pneumoniae, wherein the intact capsular polymer has at least two carbonyl groups and a bacterial toxin or toxoid, wherein the conjugate comprises a cross-linked conjugate wherein a direct covalent linkage exists between the capsular polymer and the toxin or toxoid.
[0008] U.S. Patent No. 5,693,326 provides a general method for preparing conjugate vaccines, wherein, in order to activate viral, fungal or bacterial polysaccharides, an organic cyanating agent selected from the group consisting of 1-cyano-4-(dimethylamino)-pyridinium tetrafluoroborate, N-cyanotriethyl-ammonium tetrafluoroborate and p-nitrobenzocyanate is used to form an activated carbohydrate, which is subsequently coupled to a protein or a carrier protein.
[0009] US Patent No. 5,854,416 discloses the amino acid and DNA sequence of a 37 kDa protein of Streptococcus pneumoniae, termed PsaA (Pneumococcal surface adhesion A).
[0010] US Patent No. 7,862,823 discloses a multivalent conjugate vaccine composition comprising pneumococcal capsular polysaccharide and at least two different carrier proteins (eg, DT and TT).
[0011] U.S. Patent No. 8,192,746 discloses a 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition having a CRM 197 Conjugated capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F.
[0012] US Patent No. 8,557,250 B2 discloses a method comprising contacting a mixture of a plurality of cyanate-activated immunogenic unique polysaccharides with at least one hydrazide-activated protein.
[0013] U.S. Patent No. 8,808,708 and U.S. Patent No. 8,603,484 describe 13-valent immunogenic compositions consisting of polysaccharide-protein conjugates, wherein serotypes include 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, and a carrier protein CRM 197 .
[0014] U.S. Patent Publication No. 2010 / 0074922A1 discloses an immunogenic composition containing 10 or more serotypes, wherein 19F capsular saccharide is conjugated to DT, serotype 18C capsular saccharide is conjugated to tetanus toxoid, and serotypes 1, 4, 5, 6B, 7F, 9V, 14 and 23F capsular saccharides are conjugated to protein D isolated from Haemophilus influenzae.
[0015] U.S. Patent Publication No. 2010 / 0239604 describes an immunogenic composition comprising a multivalent S. pneumoniae capsular saccharide conjugate from serotypes 19A and 19F, wherein serotype 19A is conjugated to a first bacterial toxoid, 19F is conjugated to a second bacterial toxoid, and saccharides 2-9 of the S. pneumoniae capsule are conjugated to protein D.
[0016] U.S. Patent Publication No. 2012 / 321658A1 discloses an immunogenic composition wherein serotypes 1, 3, 19A and 19F are linked directly or indirectly to a protein carrier by a chemistry other than reductive amination, and one or more different sugars are selected from a second group consisting of serotypes 4, 5, 6A, 6B, 7F, 9V, 14, 18C and 23F and are linked to the protein carrier by reductive amination.
[0017] In 140 / DEL / 2011, a pneumococcal vaccine is provided, which comprises (a) 7 or more (b) 10 or more polysaccharides from serotypes, wherein the polysaccharides are combined with a polysaccharide selected from the group consisting of DT, diphtheria toxoid, CRM 197 and conjugated to at least two or more carrier proteins of the group consisting of tetanus toxoid.
[0018] WO Publication No. 2013 / 191459A1 discloses a 15-valent pneumococcal conjugate composition comprising different serotypes of Streptococcus pneumoniae, the serotypes being derived from a CRM 197Conjugated capsular polysaccharides 1, 2, 3, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F and 23F.
[0019] WO Publication No. 2014 / 092377A1 discloses a 13-valent pneumococcal conjugate composition, wherein 12 serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, and the last serotype is a serotype with CRM 197 Conjugated 2 or 9N.
[0020] WO publication number 2014 / 092378A1 describes an immunogenic pneumococcal conjugate composition wherein 12 serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, and the remaining one is selected from the group consisting of CRM 197 Conjugated 22F or 33F.
[0021] WO Publication No. 2016 / 207905A2 discloses a multivalent pneumococcal conjugate vaccine (PCV) composition comprising: 1) a pneumococcal conjugate vaccine selected from a pneumococcal conjugate vaccine activated by CDAP and conjugated to a carrier protein CRM 197 at least 12 capsular polysaccharides of conjugated Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9N, 9V, 15B, 14, 18C, 19A, 19F, 22F, 23F and 33F, and 2) a pharmaceutically acceptable carrier, wherein the composition does not contain capsular polysaccharides from serotype 6A.
[0022] WO 2018 / 064444A1 of the present applicant describes a pneumococcal vaccine composition comprising two or more capsular pneumococcal polysaccharide serotypes, each serotype being respectively bound to a carrier protein pneumococcal surface adhesion protein A (PsaA) or PsaA and CRM 197 Combination conjugation.
[0023] Chinese patent application publication number CN 101590224 describes a 14-valent pneumococcal polysaccharide-protein conjugate vaccine containing CRM 197 Conjugated serotypes 1, 2, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F and 23F.
[0024] Chinese patent application publication number CN 103623401 discloses a 14-valent pneumococcal capsular polysaccharide-protein conjugate composition, wherein the 14 different serotypes are conjugated to CRM 197 Conjugated 1, 3, 4, 5, 6A, 6B, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F.
[0025] Chinese patent application publication number CN 103656631 provides a multivalent pneumococcal capsular polysaccharide-protein conjugate composition and its preparation method. The conjugate composition is formed by covalently linking 24 different serotypes of pneumococcal capsular polysaccharides and carrier proteins, wherein the 24 different serotypes are covalently linked to CRM 197 Conjugated 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F.
[0026] Chinese patent application publication number CN 103656632 discloses a multivalent pneumococcal capsular polysaccharide composition comprising serotype 6A and at least one selected from CRM 197 Additional serotypes from the group consisting of 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F conjugated.
[0027] Chinese patent application publication number CN 104069488 discloses a multivalent pneumococcal capsular polysaccharide vaccine containing 14 different serotypes and carrier proteins, wherein the 14 serotypes include CRM 197 Conjugated 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F.
[0028] Anderson P et al. (2003, Vaccine; 21(13-14):1554-9) disclosed a comparative study of a quadrivalent pneumococcal conjugate vaccine in which each polysaccharide type 6A, 14, 19F and 23F was conjugated with tetanus toxoid or diphtheria CRM, respectively. 197 conjugate, or a mixture of half the dose of each polysaccharide type 6A, 14, 19F and 23F with tetanus toxoid and diphtheria CRM 197 Coupling.
[0029] Nurkka et al. (2004, Ped. Inf. Dis. J., 23: 1008-1014) disclosed a study on the immunogenicity and safety of an 11-valent pneumococcal protein D conjugate vaccine, in which no serotype 3 priming effect was observed in infants who received three doses of the vaccine followed by an additional dose of the same vaccine or pneumococcal polysaccharide vaccine.
[0030] The above references disclose, among other compositions, methods, etc., multivalent pneumococcal conjugate vaccines comprising polysaccharides from one or more serotypes and conjugation of these polysaccharides to carrier proteins. In view of the different serotypes prevalent in different regions, there is a need for additional multivalent pneumococcal vaccines, including novel conjugates of polysaccharide serotypes with improved immune responses, and the development of simple and efficient production thereof.
[0031] Surprisingly, the multivalent pneumococcal conjugate vaccine composition of the present invention provides a better immune response than the original multivalent pneumococcal vaccine and existing pneumococcal conjugate vaccines. SUMMARY OF THE INVENTION
[0033] The present invention provides a 24-valent pneumococcal polysaccharide-protein conjugate vaccine composition comprising one or more serotypes of Streptococcus pneumoniae conjugated to one or more carrier proteins.
[0034] In another embodiment, the present invention provides a pneumococcal conjugate vaccine composition comprising capsular polysaccharides from serotypes of Streptococcus pneumoniae conjugated to one or more carrier proteins, wherein the serotypes include 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B.
[0035] In another embodiment, the present invention also provides a pneumococcal conjugate vaccine composition comprising a capsular polysaccharide from a serotype of Streptococcus pneumoniae conjugated to one or more carrier proteins, wherein the serotype comprises 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, and the carrier protein is selected from CRM 197 , or CRM 197 Combination with PsaA, or CRM 197 Combination with tetanus toxoid, or combination of PsaA and tetanus toxoid, or CRM 197 , a combination of PsaA and tetanus toxoid, or CRM 197 , PsaA, protein D, diphtheria toxin and tetanus toxoid.
[0036] In one embodiment, the present invention provides a pneumococcal conjugate vaccine composition comprising a capsular polysaccharide from a serotype of Streptococcus pneumoniae conjugated to a carrier protein, wherein the serotypes include 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, and the carrier protein is CRM 197 .
[0037] In one embodiment, the invention provides a pneumococcal conjugate vaccine composition comprising capsular polysaccharides from serotypes of Streptococcus pneumoniae conjugated to a carrier protein, wherein the serotypes include 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, and the carrier protein is PsaA.
[0038] In one embodiment, the present invention provides a pneumococcal conjugate vaccine composition comprising a capsular polysaccharide from a serotype of Streptococcus pneumoniae conjugated to one or more carrier proteins, wherein the serotypes include 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, and the carrier protein is CRM 197 , PsaA or a combination thereof.
[0039] In one embodiment, the present invention provides a pneumococcal conjugate vaccine composition comprising a capsular polysaccharide from a serotype of Streptococcus pneumoniae conjugated to one or more carrier proteins, wherein the serotypes include 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, and the carrier protein is CRM 197 , PsaA, tetanus toxoid, or a combination thereof. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 SEC-HPLC chromatograms showing the kinetics of conjugation reactions of (A) serotype 3 and (B) serotype 6B to PsaA.
[0041] Figure 2 Indicates (A) serotype 6A-CRM 197 and (B) SEC-HPLC chromatogram of the conjugation reaction kinetics of serotype 6A to PsaA.
[0042] Figure 3Indicates (A) serotype 8-CRM 197 and (B) SEC-HPLC chromatogram of serotype 8-PsaA conjugation reaction kinetics.
[0043] Figure 4 Indicates (A) serotype 10A-CRM 197 and (B) SEC-HPLC chromatogram of the kinetics of the serotype 10A-PsaA conjugation reaction.
[0044] Figure 5 Indicates (A) serotype 11A-CRM 197 and (B) SEC-HPLC chromatogram of the kinetics of the serotype 11A-PsaA conjugation reaction.
[0045] Figure 6 Indicates (A) serotype 12F-CRM 197 and (B) SEC-HPLC chromatogram of serotype 12F-PsaA conjugation reaction kinetics.
[0046] Figure 7 Indicates (A) serotype 15A-CRM 197 and (B) SEC-HPLC chromatogram of the kinetics of the serotype 15A-PsaA conjugation reaction.
[0047] Figure 8 Indicates (A) serotype 23A-CRM 197 and (B) SEC-HPLC chromatogram of the kinetics of the serotype 23A-PsaA conjugation reaction.
[0048] Fig. 9 Indicates (A) serotype 23B-CRM 197 and (b) SEC-HPLC chromatogram of the kinetics of the serotype 23B-PsaA conjugation reaction.
[0049] Fig.10 Indicates (A) serotype 24F-CRM 197 and (B) SEC-HPLC chromatogram of serotype 24F-PsaA conjugation reaction kinetics.
[0050] Fig.11 Indicates (A) serotype 35B-CRM 197 and (B) SEC-HPLC chromatogram of the kinetics of the serotype 35B-PsaA conjugation reaction.
[0051] Fig. 12A : Serum antibody titers of rabbits immunized with Formulation I.
[0052] Fig. 12B : Serum antibody titers of rabbits immunized with Formulation II.
[0053] definition
[0054] In the present invention, unless the context clearly indicates otherwise, the singular term "one" includes plural references. Similarly, unless the word "or" is clearly defined as referring only to a single item in a list of two or more items that is excluded from other items, the use of "or" in such a list should be interpreted as including any single item in (a) the list, (b) all items in the list, or (c) any combination of items in the list. In addition, in the present invention, the term "including" and the like are used to indicate that at least the described features are included, so that any greater number of the same features and / or one or more additional types of features are not excluded. References to "an embodiment" or similar forms herein mean that a composition, method or characteristic described in conjunction with the embodiment may be included in at least one embodiment of the present technology. Therefore, the appearance of these phrases or forms herein does not necessarily refer to the same embodiment. In addition, in one or more embodiments, various specific features, compositions, methods or characteristics may be combined in any suitable manner.
[0055] The present invention is not intended to be exhaustive or limit the present technology to the precise form disclosed herein. Although specific embodiments are disclosed herein for illustrative purposes, various equivalent modifications are possible without departing from the present technology as will be appreciated by those skilled in the relevant art. In some cases, well-known structures and functions are not shown and / or described in detail to avoid unnecessarily obscuring the description of the embodiments of the present technology. Although the steps of the method may be presented in a particular order herein, in alternative embodiments, these steps may have another appropriate order. Similarly, certain embodiments of the present technology disclosed in the context of a specific embodiment may be combined or eliminated in other embodiments. In addition, although the advantages associated with certain embodiments may be disclosed in the context of these embodiments, other embodiments may also demonstrate these advantages, and not all embodiments need to demonstrate these advantages or other advantages disclosed herein to fall within the scope of the present technology. Therefore, the present invention and related technologies may include other embodiments that are not explicitly shown and / or described herein.
[0056] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the methods belong. Although any immunogenic composition, vaccine composition, or method similar or equivalent to those described herein may also be used in the practice or testing of embodiments of the present invention, representative illustrative methods and compositions are now described.
[0057] Where a range of values is provided, it is understood that each intervening value between the upper and lower limits of that range and any other stated or intervening value in that stated range is encompassed by the methods and compositions. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed by the methods and compositions in the stated ranges, subject to any specifically excluded limits in the stated ranges. If the stated range includes one or both limits, ranges excluding either or both limits are also encompassed by the methods, compositions and combinations.
[0058] As used herein, the term "capsular polysaccharide" refers to a layer of polysaccharide external to but associated with the cell wall of S. pneumoniae of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B.
[0059] As used herein, the term "sizing" refers to reducing the size of a natural polysaccharide by various methods. These methods may include mechanical methods, such as homogenization. Reducing the size of a natural polysaccharide or "sizing" provides various advantages, including: (1) imparting high immunogenicity compared to the natural polysaccharide (2) the ratio of polysaccharide to protein in the conjugate can be altered (3) sized polysaccharides can provide greater stability of the composition.
[0060] The term "molecular weight" or "molecular size" or "average molecular size" or "average molecular weight" of a polysaccharide as used herein refers to the weight average molecular weight (Mw) of the polysaccharide measured by MALLS (multi-angle laser light scattering).
[0061] As used herein, the terms "immunogenic composition" and "vaccine composition" are used interchangeably.
[0062] As used herein, the term "carrier protein" refers to any protein or fragment thereof to which a hapten (weak antigen) is coupled, attached or conjugated, usually to enhance or promote detection of the antigen by the immune system. Examples of carrier proteins include, but are not limited to, CRMs. 197 , PsaA, tetanus toxoid and its fragments.
[0063] As used herein, the term "conjugated" is used to indicate that the S. pneumoniae capsular polysaccharide is covalently bound to a carrier protein.
[0064] As used herein, the term "adjuvant" refers to a non-antigenic component of a vaccine that promotes contact between the antigen and the immune system by affecting the type and quality of the immune response generated against the antigen, thereby enhancing the immune response to the vaccine antigen. The adjuvant causes a prolonged immune response to the antigen and can also be used to reduce the toxicity of certain antigens or provide solubility to certain antigens.
[0065] As used herein, the term "pharmaceutically acceptable carrier" refers to one or more optional components that can be added to a vaccine formulation for administration of an antigen and / or virus, which itself does not induce the production of antibodies harmful to the individual receiving the composition, and does not produce excessive toxicity when administered. Suitable carriers can be large, slowly metabolized macromolecules, such as proteins, polysaccharides, polylactic acid, polyglycolic acid, polymeric amino acids, amino acid copolymers, and inactive viral particles. The term includes one or more excipients, stabilizers, diluents, buffers or surfactants, lyophilization excipients, or combinations thereof. The pharmaceutically acceptable or pharmacologically acceptable refers to a material that is biologically or otherwise undesirable, that is, the material can be administered to an individual in a formulation or composition without causing any adverse biological effects or interacting in a harmful manner with any component of the composition containing the material. DETAILED DESCRIPTION OF THE INVENTION
[0067] The present invention provides a 24-valent pneumococcal polysaccharide-protein conjugate vaccine composition, which comprises polysaccharides from 24 different serotypes of Streptococcus pneumoniae conjugated to one or more carrier proteins.
[0068] In one embodiment, the present invention also provides a pneumococcal conjugate vaccine composition, which comprises capsular polysaccharides from 24 different serotypes of Streptococcus pneumoniae conjugated to a carrier protein, wherein the serotypes include 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the carrier protein is selected from CRM 197 , or CRM 197 A combination of PsaA or CRM 197 and tetanus toxoid, or a combination of PsaA and tetanus toxoid, or CRM 197 , PsaA and tetanus toxoid.
[0069] In one embodiment, the present invention provides a 24-valent pneumococcal polysaccharide-protein conjugate vaccine composition, the composition is selected from serotypes of Streptococcus pneumoniae 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein at least 13 serotypes are consistent with CRM 197 conjugated with PsaA, and the remaining serotypes were conjugated with PsaA.
[0070] In a preferred embodiment, the present invention provides a 24-valent pneumococcal polysaccharide-protein conjugate vaccine composition comprising capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B of Streptococcus pneumoniae, wherein the capsular polysaccharides of serotypes 1, 4, 5, 6B, 7F, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B are combined with CRM. 197 The serotypes 3, 6A, 8, 10A, 11A, 12F, 15A, 23A, 23B, 24F, and 35B capsular polysaccharides were conjugated to PsaA.
[0071] In one embodiment, the present invention provides a 24-valent pneumococcal polysaccharide-protein conjugate vaccine composition comprising a CRM 197 The carrier protein is conjugated to a capsular polysaccharide from different serotypes of Streptococcus pneumoniae selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B.
[0072] In one embodiment, the present invention provides a 24-valent pneumococcal polysaccharide-protein conjugate vaccine composition, which comprises capsular polysaccharides from different serotypes of Streptococcus pneumoniae selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to a PsaA carrier protein.
[0073] In a preferred embodiment, the present invention provides a 24-valent pneumococcal polysaccharide-protein conjugate vaccine composition comprising capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B of S. pneumoniae, wherein the capsular polysaccharides from serotypes 3, 6A, 8, 10A, 11A, 12F, 15A, 23A, 23B, 24F and 35B are conjugated to PsaA, and the capsular polysaccharides from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM. 197 and tetanus toxoid combined conjugation.
[0074] In one embodiment, the present invention provides a pneumococcal vaccine composition comprising pneumococcal polysaccharides, wherein one or more pneumococcal polysaccharides are native pneumococcal polysaccharides.
[0075] In another embodiment, the present invention provides a pneumococcal vaccine composition comprising pneumococcal polysaccharides, wherein one or more pneumococcal polysaccharides are fragmented, and the average molecular weight of each fragmented pneumococcal polysaccharide is less than the average molecular weight of the native pneumococcal polysaccharide and can be in the range of 50-1000 kDa.
[0076] In another embodiment, the present invention provides capsular polysaccharides isolated and purified from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B of Streptococcus pneumoniae, wherein the molecular weight of each polysaccharide is between about 50 and 1000 kDa, preferably, the average molecular weight (Mw) is between 100-1000, 200-800, 250-600 or 300-400, 70-150 or 75-125 kDa.
[0077] In other embodiments, the present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition comprising polysaccharides from 24 different pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, selected from CRM 197 , or CRM 197 Combination with PsaA, or CRM 197 Combination with tetanus toxoid, or combination of PsaA and tetanus toxoid, or CRM 197 , PsaA conjugated to a carrier protein in a combination with tetanus toxoid, wherein the molecular weight of the polysaccharide-protein conjugate is between about 500 kDa and about 5000 kDa; 1000 kDa to about 10000 kDa; about 1500 kDa to 15000 kDa; about 2000 kDa to 20000 kDa; about 2500 kDa to 25000 kDa; or about 3000 kDa to about 30000 kDa.
[0078] In another preferred embodiment, the present invention provides a 24-valent pneumococcal polysaccharide-protein conjugate vaccine composition comprising about 2.2-2.4 μg of each capsular polysaccharide from serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F, and 35B of S. pneumoniae, and about 4.4 μg of each capsular polysaccharide from serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F, and 35B, wherein each capsular polysaccharide from serotypes 1, 3, 4, 5, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F, and 35B is combined with about 30-35 μg of CRM. 197 The carrier protein was conjugated and each capsular polysaccharide from serotypes 3, 6A, 8, 10A, 11A, 12F, 15A, 23A, 23B, 24F and 35B was conjugated to approximately 20-30 μg of PsaA.
[0079] In another preferred embodiment, the present invention provides a 24-valent pneumococcal polysaccharide-protein conjugate vaccine composition, which comprises each capsular polysaccharide of serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B of Streptococcus pneumoniae, wherein each capsular polysaccharide is about 2.2-2.4 μg, and about 4.4 μg of 6B, wherein each capsular polysaccharide is conjugated to about 40-80 μg of PsaA.
[0080] In another preferred embodiment, the present invention provides a 24-valent pneumococcal polysaccharide-protein conjugate vaccine composition comprising about 2.2-2.4 μg of each capsular polysaccharide of serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F, and 35B of S. pneumoniae, and about 40-80 μg of each capsular polysaccharide of serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F, and 35B of S. pneumoniae. 197 Conjugation.
[0081] In another aspect, the present invention provides an isolated Streptococcus pneumoniae serotype 15A having an average molecular weight between 50-1000 kDa and a glycerol content in the range of 5-18%.
[0082] After the polysaccharide was treated with hydrofluoric acid (HF) to release glycerol, the presence of glycerophosphate side chains was determined by high performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD).
[0083] In another aspect, the present invention provides an isolated S. pneumoniae serotype 35B capsular polysaccharide having an average molecular weight between 50-1000 kDa and an acetate content in the range of 2-10%, preferably 2-8%.
[0084] In another embodiment, the present invention provides a pneumococcal conjugate vaccine composition comprising pneumococcal polysaccharides, wherein each pneumococcal polysaccharide is activated using 1-cyano-4-dimethylamino-tetrafluoroborate pyridinium (CDAP) to form a cyanate prior to conjugation to a carrier protein.
[0085] In another embodiment, the present invention provides a pneumococcal conjugate vaccine composition comprising pneumococcal polysaccharides, wherein one or more pneumococcal polysaccharides are directly coupled to an amino group of a carrier protein or are coupled to an amino group via a spacer.
[0086] In another embodiment, the present invention provides a pneumococcal conjugate vaccine composition comprising pneumococcal polysaccharide, wherein the spacer is cystamine, cysteamine, hexamethylenediamine, adipic acid dihydrazide (ADH), EDAC or EDC.
[0087] The PsaA carrier protein according to the present invention is a modified PsaA and does not include the wild-type hydrophobic N-terminal leader peptide.
[0088] The present invention provides a pneumococcal conjugate vaccine composition, which comprises one or more serotype pneumococcal polysaccharides and a carrier protein, wherein the PsaA carrier protein comprises 290 amino acids.
[0089] The pneumococcal conjugate vaccine composition comprises a capsule pneumococcal polysaccharide serotype, each serotype being conjugated to a carrier protein alone, referred to herein as a polysaccharide-protein conjugate and / or conjugate. When included in the pneumococcal vaccine composition described herein, it is a multivalent pneumococcal polysaccharide-protein conjugate vaccine (also referred to herein as a multivalent conjugate vaccine, a conjugate vaccine and / or a polysaccharide-protein conjugate vaccine). In addition to the multivalent conjugate vaccine, the present invention also provides a method for preparing and / or administering the multivalent conjugate vaccine to a subject in need thereof.
[0090] A carrier protein is a non-toxic, non-reactive protein in sufficient quantity and purity. In some embodiments, the present invention provides a pneumococcal conjugate vaccine composition comprising one or more carrier proteins conjugated to one or more Streptococcus pneumoniae polysaccharides (also referred to herein as "pneumococcal polysaccharides"). By conjugating pneumococcal polysaccharides to carrier proteins, pneumococcal polysaccharides have higher immunogenicity than unconjugated pneumococcal polysaccharides.
[0091] In some embodiments of the present invention, the combination of carrier proteins used includes two or more carrier proteins, such as PsaA, CRM 197, protein D, diphtheria toxoid and tetanus toxoid (TT).
[0092] In another embodiment, the pneumococcal polysaccharide-protein conjugate composition of the present invention further comprises one or more of the following: a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, a surfactant, a solvent and / or a lyophilization excipient. Suitable buffers include, but are not limited to, Tris (aminobutyryl alcohol), phosphate, acetate, borate, citrate, glycine, histidine and succinate, etc. Suitable surfactants include, but are not limited to, polysorbate-20, polysorbate-40, polysorbate-60 (Tween 60), polysorbate-80 (Tween 80), copolymers of ethylene oxide (EO), propylene oxide (PO) and / or butylene oxide (BO), poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338 and poloxamer 407, octanol, sorbitan trioleate (Span 85), and sorbitan monolaurate, etc., at a concentration of about 0.001% to about 2%.
[0093] The compositions of the present invention are formulated in a buffered saline solution at a pH of 5.0-8.0.
[0094] In some embodiments, pneumococcal polysaccharides can be extracted from one or more microorganisms (e.g., Streptococcus pneumoniae) according to conventional methods. For example, pneumococcal polysaccharides can be prepared according to known procedures. In addition, the purification of pneumococcal polysaccharides can be carried out according to the steps described in PCT publication WO 2016 / 174683 A1.
[0095] The extracted pneumococcal polysaccharide can be purified according to conventional methods and can be used in its natural form. In other embodiments, the extracted and purified pneumococcal polysaccharide can be pulverized to obtain one or more parts of pneumococcal polysaccharide, and the average molecular weight of each part of pneumococcal polysaccharide is less than the average molecular weight of the extracted and purified pneumococcal polysaccharide.
[0096] In other embodiments, the extracted and purified pneumococcal polysaccharide may be activated before being conjugated to one or more carrier proteins. For example, the extracted and purified pneumococcal polysaccharide may be activated (e.g., chemically) before being conjugated to one or more carrier proteins. Each activated pneumococcal polysaccharide may be conjugated to a carrier protein that forms a polysaccharide-protein conjugate (e.g., a glycoconjugate) individually. In other embodiments, one or more activated pneumococcal polysaccharides may be conjugated to a single carrier protein. The conjugate may be prepared by known techniques.
[0097] In some embodiments, pneumococcal polysaccharides can be chemically activated and then conjugated to a carrier protein according to known techniques, such as those described in U.S. Pat. Nos. 4,365,170, 4,673,574, and 4,902,506. For example, pneumococcal polysaccharides can be activated by oxidizing the terminal hydroxyl groups to aldehydes using an oxidizing agent such as a periodate (e.g., sodium periodate, potassium periodate, or periodic acid), specifically by random oxidation cleavage of one or more ortho-hydroxyl groups of the saccharide and formation of one or more active aldehyde groups.
[0098] Pneumococcal polysaccharides can also be activated by CDAP (1-cyano-4-dimethylaminopyridinium tetrafluoroborate) and subsequently bound to one or more carrier proteins (e.g., PsaA, CRM 197 , PspA) or a combination thereof. In other embodiments, pneumococcal polysaccharides activated by CDAP to form cyanate esters can be directly conjugated to one or more carrier proteins or conjugated using a spacer (e.g., a linker). The spacer can be coupled to an amino group on a carrier protein. In some embodiments, the spacer can be cystamine or cysteamine, which produces a sulfonylated polysaccharide that can be connected to a maleimide-activated carrier protein (e.g., using GMBS) or a haloacetylated carrier protein (e.g., using iodoacetimide, ethyl iodoacetimide HCl, SIAB, SIA, SBAP and / or N-succinimidyl bromoacetate) through a thioether bond. In other embodiments, hexamethylenediamine or adipic acid dihydrazide (ADH) is used to couple cyanate esters, and amino-derivatized sugars are conjugated to carrier proteins using carboxyl groups on a protein carrier using a carbodiimide (e.g., EDAC or EDC) chemical process. Such conjugates are described in PCT Publication WO 93 / 15760, PCT Publication WO 95 / 08348, PCT Publication WO 96 / 29094, and Chu et al. 1983, Infect. Immunity 40:245-256.
[0099] Other suitable activation and / or coupling techniques used with the polysaccharide-protein conjugates and vaccine compositions of the present invention include the use of carbodiimides, hydrazides, active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC, TSTU, and other methods described in PCT publication WO 98 / 42721. For example, the composition may involve a carbonyl linker, which may be formed by reacting the free hydroxyl groups of the sugar with CDI (see Bethell et al. 1979, J. Biol. Chem. 254: 2572-4; Hearn et al., 1981, J. Chromatogr. 218: 509-18), and then coupled to the protein to form a carbamate bond. In some embodiments, the ectopic terminus may be reduced to a primary hydroxyl group, optional protection / deprotection of the primary hydroxyl group, reaction of the primary hydroxyl group with CDI to form a CDI carbamate intermediate and coupling the CDI carbamate intermediate to an amino group on the protein.
[0100] For example, another suitable activation and / or coupling technique for use with the polysaccharide-protein compositions and vaccine compositions of the present invention includes the following method: sized pneumococcal polysaccharide (e.g., about 6 mL of sized polysaccharide at a concentration of about 10 mg / mL) and CDAP (e.g., about 100 mg / mL of acetonitrile (w / v)) can be mixed in a glass bottle at a ratio of about 1:1 (e.g., by stirring for about 1 minute). The pH of the polysaccharide solution can be adjusted as needed (e.g., adjusted to about 9.25 using about 0.2 M triethylamine and stirred at room temperature for 3 minutes). In addition, PsaA (e.g., about 4 mL of a solution at a concentration of about 15 mg / mL) can be slowly added to the activated pneumococcal polysaccharide (e.g., at a ratio of about 1:1 (Ps: carrier protein)). The pH of the reaction can be adjusted (e.g., adjusted to about 9.05 using 0.2 M trimethylamine), and the reaction can be continued (e.g., by stirring at room temperature for 5 hours). The reaction mixture can be quenched (e.g., by adding an excess concentration of glycine).
[0101] In some embodiments, the reaction mixture can be secondary filtered using a membrane (e.g., a MWCO membrane of 100K) and can be purified by size exclusion chromatography. The ultrafiltered and purified fractions can be analyzed using SEC-MALLS and anthrone methods. The analyzed fractions containing the conjugate can be combined and sterile filtered (e.g., using a 0.2 μm filter).
[0102] After the pneumococcal polysaccharide is conjugated to one or more carrier proteins, the polysaccharide-protein conjugate can be purified by a variety of techniques (e.g., with respect to the enrichment of the amount of the polysaccharide-protein conjugate). These techniques include, but are not limited to, concentration / diafiltration operations, precipitation / elution, column chromatography, and depth filtration. For example, after the conjugate is purified, the conjugate can be compounded to form a pneumococcal polysaccharide-protein conjugate composition of the present invention, which can be used as a vaccine.
[0103] In some embodiments, the present invention provides a method for preparing a polysaccharide-protein composition of a pneumococcal vaccine composition described herein, wherein the method further comprises formulating the polysaccharide-protein composition into a pneumococcal vaccine composition comprising an adjuvant, an excipient, and a buffer.
[0104] In some embodiments, the invention provides a method for preparing the polysaccharide-protein conjugate of the pneumococcal vaccine composition described herein, wherein the adjuvant is aluminum phosphate.
[0105] In some embodiments, the present invention provides a method of preventing or treating a subject in need thereof, comprising administering to the subject in need thereof a pneumococcal vaccine composition described herein.
[0106] In some embodiments, the subject has a disease mediated by S. pneumoniae, such as invasive pneumococcal disease (IPD).
[0107] In one embodiment, the subject is a human, e.g., an infant (less than about 1 year old), a toddler (about 12 months to about 24 months old), a child (about 2 years to about 5 years old), an older child (about 5 years to about 13 years old), a teenager (about 13 years to about 18 years old), an adult (about 18 to 65 years old), or an elderly person (about 65 years old and older).
[0108] In some embodiments, the invention provides a method of inducing an immune response comprising administering to a subject an immunologically effective amount of a pneumococcal conjugate vaccine composition described herein.
[0109] In one embodiment, the method of inducing an immune response comprises administering systemically, subcutaneously and / or mucosally to a subject a pneumococcal conjugate vaccine composition described herein.
[0110] In some embodiments, the amount of each conjugate in a dose of the vaccine composition of the invention is an amount sufficient to induce an immunoprotective response, such as an immunoprotective response without significant adverse reactions. Although the amount of each conjugate may vary depending on the pneumococcal serotype, each dose of the vaccine composition may include about 0.1 μg to about 50 μg of each pneumococcal polysaccharide, about 0.1 μg to about 10 μg, or about 1 μg to about 5 μg of each pneumococcal polysaccharide, which is conjugated to each carrier protein containing about 1.5 μg to about 5 μg of the carrier protein.
[0111] In another embodiment, the present invention provides a pneumococcal conjugate vaccine composition comprising pneumococcal polysaccharide and a carrier protein having a percentage ratio of protein to polysaccharide (protein / PS) of about 0.3 to about 2.0 protein / PS, preferably 0.5-1.5.
[0112] In some embodiments, the purified polysaccharide prior to conjugation has a molecular weight between 10 kDa-2000 kDa. In other such embodiments, the polysaccharide has a molecular weight of between 50kDa-2000kDa; between 50kDa and 2000kDa; between 50kDa and 1750kDa; between 50kDa and 1500kDa; between 50kDa and 1250kDa; between 50kDa and 1000kDa; between 50kDa and 750kDa; between 50kDa and 500kDa; between 100kDa and 2000kDa; between 100kDa and 2000kDa; between 100kDa and 1750kDa; between 100kDa and 1500kDa; between 100kDa and 1250kDa; between 100kDa and 1000kDa; between 100kDa and 750kDa; between 100kDa and 500kDa.
[0113] In other embodiments, the present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition comprising one or more polysaccharide-protein conjugates having a molecular weight of between about 1000 kDa to about 10000 kDa, about 1500 kDa to about 15000 kDa, about 2000 kDa to about 20000 kDa, about 2500 kDa to about 25000 kDa, or about 3000 kDa to about 30000 kDa.
[0114] The pneumococcal polysaccharide-protein conjugate vaccine composition of the present invention can be prepared using known methods. For example, the pneumococcal polysaccharide-protein conjugate vaccine composition can be formulated with a pharmaceutically acceptable diluent or carrier (e.g., water or saline). In addition, the pneumococcal polysaccharide-protein conjugate vaccine composition may further include one or more of the following: a buffer, a preservative or stabilizer, a polysorbate, an adjuvant such as an aluminum compound (e.g., aluminum hydroxide, aluminum phosphate, or aluminum hydroxyphosphate), and / or a lyophilized adjuvant. The inclusion of any of the above compounds in the pneumococcal polysaccharide-protein conjugate vaccine composition of the present invention may be selected as a function of the mode and route of administration to a subject in need thereof, and may be further based on standard medical practice.
[0115] In another preferred embodiment, the present invention provides a 24-valent immunogenic composition comprising: 197Conjugated pneumococcal capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 14, 18C, 19A, 19F, 23F, 11A, 12F, 15A, 22F, 23A, 23B, 24F, 33F and 35B, wherein the composition has a pH of 4 to 7 and comprises: about 4.4 μg / 0.5 mL of 6B; about 2.2-4 μg / 0.5 mL of all other polysaccharides; about 40-80 μg / 0.5 mL of CRM 197 ; 0.2-2 mg / 0.5 mL aluminum phosphate; about 1-10 mM succinate buffer; about 0.5-25% sodium chloride; 0.002-0.2% polysorbate 80; and 4 mg / mL and 10 mg / 0.5 mL 2-phenoxyethanol.
[0116] In another preferred embodiment, the present invention provides a 24-valent immunogenic composition comprising CRM 197 Capsular polysaccharides from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F of Pneumococcus conjugated to carrier protein, and capsular polysaccharides from serotypes 3, 6A, 8, 10A, 11A, 12F, 15A, 23A, 23B, 24F, and 35B conjugated to PsaA, wherein the composition has a pH of 4 to 7 and comprises: about 4.4 μg / 0.5 mL of 6B; about 2.2-4 μg / 0.5 mL of all other polysaccharides; and 20-40 μg / 0.5 mL of CRM from pneumococcus. 197 ; from 20-40 μg / 0.5 mL of PsaA; 0.2-2 mg / 0.5 mL of aluminum phosphate; about 1-10 mM sodium buffer; about 0.5-25% sodium chloride; 0.002-0.2% polysorbate 80; and 4 mg / mL and 10 mg / 0.5 mL of 2-phenoxyethanol.
[0117] In another preferred embodiment, the present invention provides a 24-valent immunogenic composition comprising pneumococcal capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 14, 18C, 19A, 19F, 23F, 11A, 12F, 15A, 22F, 23A, 23B, 24F, 33F and 35B conjugated to PsaA, respectively, wherein the pH of the composition is 4 to 7, and contains: about 4.4 μg / 0.5 mL of 6B; about 2.2-4 μg / 0.5 mL of all other polysaccharides; about 40-80 μg / 0.5 mL of PsaA; 0.2-2 mg / 0.5 mL of aluminum phosphate; about 1-10 mM succinate buffer; about 0.5-25% sodium chloride; 0.002-0.2% polysorbate 80; and 4 mg / mL and 10 mg / 0.5 mL of 2-phenoxyethanol.
[0118] In some embodiments, the present invention provides a method for preparing a 24-valent pneumococcal polysaccharide-protein conjugate composition, the composition comprising a pneumococcal polysaccharide selected from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 14, 18C, 19A, 19F, 23F, 11A, 12F, 15A, 22F, 23A, 23B, 24F, 33F and 35B, wherein the carrier protein is CRM 197 The method for preparing a 24-valent pneumococcal polysaccharide-protein conjugate comprises the following steps;
[0119] (a) 24 activated pneumococcal polysaccharides were mixed with CRM 197 Carrier protein conjugation,
[0120] (b) filtering and purifying the conjugate using size exclusion chromatography,
[0121] (c) analyzing the purified fractions using SEC-MALLS, pooling the fractions containing each of the 24 conjugates, and filter-sterilizing the monovalent conjugate fractions, and
[0122] (d) formulating the 24 conjugates obtained in step (c), an adjuvant, one or more excipients and a buffer to prepare a 24-valent pneumococcal polysaccharide-protein conjugate composition.
[0123] In some embodiments, the present invention provides a method for preparing a 24-valent pneumococcal polysaccharide-protein conjugate composition, the composition comprising a pneumococcal polysaccharide selected from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the capsular polysaccharide from serotypes 3, 6A, 8, 10A, 11A, 12F, 15A, 23A, 23B, 24F and 35B is conjugated to PsaA, and the capsular polysaccharide from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B is conjugated to CRM. 197 Conjugation. The method for preparing a 24-valent pneumococcal polysaccharide-protein conjugate comprises the following steps;
[0124] (a) Polysaccharides of serotypes 3, 6A, 8, 10A, 11A, 12F, 15A, 23A, 23B, 24F and 35B were conjugated to PsaA, and capsular polysaccharides of serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F were conjugated to CRM 197 Conjugation,
[0125] (b) filtering and purifying the conjugate using size exclusion chromatography,
[0126] (c) analyzing the purified fractions using SEC-MALLS, pooling the fractions containing each of the 24 conjugates, and filter-sterilizing the fractions containing the monovalent conjugate, and
[0127] (d) formulating the 24 conjugates obtained in step (a), an adjuvant, one or more excipients and a buffer to prepare a 24-valent pneumococcal polysaccharide-protein conjugate composition.
[0128] In some embodiments, the 24-valent pneumococcal polysaccharide-protein conjugate composition can be filtered (eg, aseptically).
[0129] In one embodiment, CDAP is used to activate pneumococcal polysaccharide. In another example, the adjuvant used is aluminum phosphate.
[0130] Each of the 24-valent conjugates can be adsorbed onto an aluminum salt, such as aluminum hydroxide, aluminum phosphate, or a mixture of aluminum hydroxide and aluminum phosphate, either individually or together as a mixture. The adsorbent can be prepared in situ or added during the manufacturing process. The preparation of the 24-valent conjugate can be carried out by adding each conjugate in turn to a vessel or container, or by preparing a vessel containing the CRM. 197 Separate solutions of the conjugate (Part 1) and the PsaA conjugate (Part 2) are prepared and Part 1 is added to Part 2, or vice versa.
[0131] The composition of the present invention can be formulated into a unit dose (e.g., a unit dose vial), multiple doses (e.g., a multiple dose vial) or a pre-filled syringe. The composition of the present invention may further comprise one or more preservatives selected from thimerosal, 2-phenoxyethanol, etc., in an amount ranging from about 4 mg / mL to about 20 mg / mL.
[0132] In some embodiments, the present invention also provides an immunogenic composition (e.g., a vaccine), such as a pneumococcal polysaccharide-protein conjugate composition, which is administered in a single dose of about 0.5 mL and is formulated to contain at least the following: about 2.2-4.4 μg of two or more pneumococcal polysaccharide serotypes, about 1 μg to about 10 μg of each PsaA serotype, about 2 μg to about 5 μg of each CRM 197 serotype, about 0.2 mg to about 1 mg of an adjuvant (eg, aluminum phosphate) and one or more excipients (eg, sodium chloride and / or a buffer).
[0133] The compositions of the present invention can be administered to a subject in need of the compositions by any number of conventional routes used in the vaccine field. For example, the compositions of the present invention can be administered systemically, such as parenterally (e.g., subcutaneously, intramuscularly, intradermally and / or intravenously) or transmucosally (e.g., orally and / or nasally).
[0134] In some embodiments, the present invention also provides a method of inducing an immune response to one or more S. pneumoniae capsular polysaccharides conjugated to one or more carrier proteins in an individual in need thereof. The method of inducing an immune response comprises administering an immunologically effective amount of a composition described herein to a subject in need thereof.
[0135] According to the methods of the present invention, the subjects targeted by the compositions described herein are humans, such as infants (less than about 1 year old), toddlers (about 12 months to about 24 months old), children (about 2 years old to about 5 years old), older children (about 5 years old to about 13 years old), adolescents (about 13 years old to about 18 years old), adults (about 18 years old to about 65 years old) or the elderly (about 65 years old and above).
[0136] As used herein, an "effective amount" of the composition of the present invention refers to an amount required to induce an immune response in a subject to which the composition is administered. The immune response is characterized by the presence of one or more pneumococcal antigen-specific antibodies in the host, which significantly reduces the likelihood or severity of pneumococcal infection during a subsequent challenge. DETAILED DESCRIPTION
[0137] The following examples are provided to illustrate the present invention and are for illustrative purposes only and should not be construed as limiting the scope of the present invention.
[0138] Example 1: Pneumococcal capsular polysaccharide-CRM 197 Preparation of conjugates
[0139] Pneumococcal capsular polysaccharide - CRM of pneumococcal serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F 197 The conjugate was prepared according to the procedures described in PCT publication WO 2016 / 207905.
[0140] Polysaccharide CRMs for pneumococcal serotypes 6A, 8, 10A, 11A, 12F, 15A, 23A, 23B, 24F, and 35B were prepared as follows: 197 Conjugate:
[0141] a) Pneumococcal polysaccharide serotype 6A and CRM 197 Protein activation and conjugation.
[0142] 1000 mg (68.5 mL at a concentration of 14.6 mg / mL) of mechanically ground polysaccharide serotype 6A and 5.0 mL of CDAP (100 mg / mL acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:0.5 (PS:CDAP) and stirred for 1 minute. The pH of the polysaccharide solution was adjusted to 9.0 with 8.0 mL of 0.2 M triethylamine and stirred for 1 minute at room temperature (RT). 1000 mg of CRM 197 (66.7 mL, concentration 15.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1.0:1.0 (PnPs:CRM).
[0143] The pH of the reaction was adjusted to 9.0 with 1.0 mL of 0.2 M triethylamine, the reaction was stirred at room temperature for 3-5 hours, and then the reaction was quenched by adding excess concentration of glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Figure 2 A).
[0144] The reaction mixture was diafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified using size exclusion chromatography. Each component was analyzed using the SEC-MALLS method and the anthrone method, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0145] b) Pneumococcal polysaccharide serotype 8 and CRM 197 Protein activation and conjugation.
[0146] 1000 mg (200.0 mL at a concentration of 5.0 mg / mL) of mechanically ground polysaccharide serotype 8 and 4.0 mL of CDAP (100 mg / mL acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:0.4 (PS:CDAP) and stirred for 1 minute. The pH of the polysaccharide solution was adjusted to 9.0 with 7.7 mL of 0.2 M triethylamine and stirred at room temperature (RT) for 1 minute. 800 mg of CRM 197 (53.33 mL, concentration 15.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1.0:0.8 (PnPs:CRM).
[0147] The pH of the reaction was adjusted to 9.0 with 1.5 mL of 0.2 M triethylamine, the reaction was stirred at room temperature for 3-5 hours, and then the reaction was quenched by adding excess concentration of glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Figure 3 A).
[0148] The reaction mixture was re-filtered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0149] c) Pneumococcal polysaccharide serotype 10A and CRM 197 Protein activation and conjugation.
[0150] 1000 mg (142.8 mL, 7.0 mg / mL) of mechanically ground 10A polysaccharide and 8.0 mL of CDAP (100 mg / mL, acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:0.8 (PS:CDAP) and stirred for 1 min. The pH of the polysaccharide solution was adjusted to 9.0 with 13.0 mL of 0.2 M triethylamine and stirred for 1 min at room temperature (RT). 900 mg of CRM 197 (concentration of 15.0 mg / mL, 60.0 mL) was slowly added to the activated polysaccharide at a ratio of 1.0:0.9 (PnPs:CRM).
[0151] The pH of the reaction was adjusted to 9.0 with 2.5 mL of 0.2 M triethylamine, and the reaction was stirred at room temperature for 3-5 hours, and then quenched by adding excess glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Figure 4 A).
[0152] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0153] d) Pneumococcal polysaccharide serotype 11A and CRM 197 Protein activation and conjugation.
[0154] 1000 mg (125.0 mL, 8.0 mg / mL) of mechanically ground polysaccharide serotype 11A and 5.0 mL of CDAP (100 mg / mL acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:0.5 (PS:CDAP) and stirred for 1 min. The pH of the polysaccharide solution was adjusted to 9.0 with 10.0 mL of 0.2 M triethylamine and stirred for 1 min at room temperature (RT). 1000 mg of CRM 197 (66.7 mL, concentration 15.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1.0:1.0 (PnPs:CRM).
[0155] The pH of the reaction was adjusted to 9.0 with 2.5 mL of 0.2 M triethylamine, and the reaction was stirred at room temperature for 3-5 hours, and then quenched by adding excess glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Figure 5 A).
[0156] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0157] e) Pneumococcal polysaccharide serotype 12F and CRM 197 Protein activation and conjugation.
[0158] 1000 mg (concentration of 10.0 mg / mL, 100.0 mL) of mechanically ground polysaccharide serotype 12F and 5.0 mL of CDAP (100 mg / mL acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:0.5 (PS:CDAP) and stirred for 1 minute. The pH of the polysaccharide solution was adjusted to 9.0 with 10.6 mL of 0.2 M triethylamine and stirred for 1 minute at room temperature (RT). 800 mg of CRM 197 (53.3 mL, concentration 15.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1.0:0.8 (PnPs:CRM).
[0159] The pH of the reaction was adjusted to 9.0 with 1.0 mL of 0.2 M triethylamine, and the reaction was stirred at room temperature for 3-5 hours, and then quenched by adding excess glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Figure 6 A).
[0160] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0161] f) Pneumococcal polysaccharide serotype 15A and CRM 197 Protein activation and conjugation.
[0162] 1000 mg (66.7 mL at a concentration of 15.0 mg / mL) of mechanically ground polysaccharide serotype 15A and 10.0 mL of CDAP (100 mg / mL acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:1.0 (PS:CDAP) and stirred for 1 minute. The pH of the polysaccharide solution was adjusted to 9.0 with 18.0 mL of 0.2 M triethylamine and stirred for 1 minute at room temperature (RT). 1000 mg of CRM 197 (53.3 mL, concentration 15.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1.0:0.8 (PnPs:CRM).
[0163] The pH of the reaction was adjusted to 9.0 with 1.0 mL of 0.2 M triethylamine, and the reaction was stirred at room temperature for 3-5 hours, and then quenched by adding excess glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Figure 7 A).
[0164] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods. The fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0165] g) Pneumococcal polysaccharide serotype 23A and CRM 197 Protein activation and conjugation.
[0166] 1000 mg (83.3 mL at a concentration of 15.0 mg / mL) of mechanically ground polysaccharide serotype 23A and 10.0 mL of CDAP (100 mg / mL acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:1.0 (PS:CDAP) and stirred for 1 minute. The pH of the polysaccharide solution was adjusted to 9.0 with 14.9 mL of 0.2 M triethylamine and stirred for 1 minute at room temperature (RT). 800 mg of CRM 197 (53.3 mL, concentration 15.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1.0:0.8 (PnPs:CRM).
[0167] The pH of the reaction was adjusted to 9.0 with 1.7 mL of 0.2 M triethylamine and the reaction was stirred at room temperature for 3-5 hours, and then the reaction was quenched by adding excess glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Figure 8 A).
[0168] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods. The fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0169] h) Pneumococcal polysaccharide serotype 23B and CRM 197 Protein activation and conjugation.
[0170] 1000 mg (100.0 mL of 10.0 mg / mL concentration) of mechanically ground polysaccharide serotype 23B and 2.0 mL of CDAP (100 mg / mL acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:0.2 (PS:CDAP) and stirred for 1 min. The pH of the polysaccharide solution was adjusted to 9.0 with 3.5 mL of 0.2 M triethylamine and stirred for 1 min at room temperature (RT). 1000 mg of CRM 197 (66.7 mL, concentration 15.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1.0:1.0 (PnPs:CRM).
[0171] The pH of the reaction was adjusted to 9.0 with 2.2 mL of 0.2 M triethylamine, and the reaction was stirred at room temperature for 3-5 hours, and then quenched by adding excess glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Fig. 9 A).
[0172] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods. The fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0173] i) Pneumococcal polysaccharide serotype 24F and CRM 197 Protein activation and conjugation.
[0174] 1000 mg (100.0 mL of 10.0 mg / mL concentration) of mechanically ground polysaccharide serotype 24F and 5.0 mL of CDAP (100 mg / mL acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:0.5 (PS:CDAP) and stirred for 1 min. The pH of the polysaccharide solution was adjusted to 9.0 with 10.6 mL of 0.2 M triethylamine and stirred for 1 min at room temperature (RT). 800 mg of CRM 197 (53.3 mL, concentration 15.0 mg / mL) was slowly added to the activated polysaccharide (PnPs:CRM) at a ratio of 1.0:0.8.
[0175] The pH of the reaction was adjusted to 9.0 with 1.0 mL of 0.2 M triethylamine, and the reaction was stirred at room temperature for 3-5 hours, and then quenched by adding excess glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Fig.10 A).
[0176] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods. The fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0177] j) Pneumococcal polysaccharide serotype 35B and CRM 197 Protein activation and conjugation.
[0178] 1000 mg (100.0 mL of 10.0 mg / mL concentration) of mechanically ground 35B polysaccharide and 5.0 mL of CDAP (100 mg / mL acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:0.5 (PS:CDAP) and stirred for 1 minute. The pH of the polysaccharide solution was adjusted to 9.0 with 5.0 mL of 0.2 M triethylamine and stirred for 1 minute at room temperature (RT). 1000 mg of CRM 197 (66.7 mL, concentration 15.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1.0:1.0 (PnPs:CRM).
[0179] The pH of the reaction was adjusted to 9.0 with 1.6 mL of 0.2 M triethylamine, and the reaction was stirred at room temperature for 3-5 hours, and then quenched by adding excess glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Fig.11 A).
[0180] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0181] Example 2: Preparation of Pneumococcal Capsular Polysaccharide PsaA Conjugate
[0182] A) PsaA preparation:
[0183] The PsaA gene was amplified by PCR from Streptococcus pneumoniae serotype 4 without its hydrophobic leader peptide sequence. The gene sequence was confirmed and cloned into Escherichia coli using a constructed vector (pBE66) for efficient expression.
[0184] The glycerol stock culture encoding the PSaA gene was revived in 20 mL of LB medium containing 1 mL of the glycerol stock in a 150 mL conical flask. The culture was incubated at 200 rpm and 37°C for about 6 hours. The final OD 600nm The revived culture was transferred to 1 L of seed culture in a 5 L conical flask. The culture was cultured at 200 rpm and 37 °C for about 10 hours until the final OD 600nm 3. The seed culture was aseptically transferred to a 20L fermenter containing the following medium components: peptone (HyPeptone) 6g / L, yeast extract 12g / L, potassium dihydrogen phosphate 13.5g / L, diammonium phosphate 4g / L, citric acid 1.7g / L, MgSO4.7H2O 1.2g / L, glucose 4g / L, ammonium hydrochloride 10mg / L, and 1mL / L trace elements (for example, 100mL of the trace elements FeCl3 2.7g, ZnCl2 0.2g, CoCl2.6H2O 0.2g, Na2MoO4.2H2O 0.2g, CuSO45H2O 0.1g, boric acid 0.05g, CaCl2 2H2O 0.1g, HCL concentration 10mL). The initial fermentation was performed at OD 600nmThe pH was maintained at 7 ± 0.2 throughout the fermentation, and the fermentation was carried out with 20% o-phosphoric acid and 12.5% ammonium hydroxide. When the glucose level dropped below 0.5 g / L, batch feeding was initiated at a steady rate of 3-4 g / L / hr, and the DO% was maintained > 20% throughout the aerobic fermentation. The cells were cultured in a fermenter and the cell pellets were obtained by centrifugation. The cells were lysed using a cell lysis device (Panda). The lysate was centrifuged at 10,000 g and the clarified supernatant was purified.
[0185] The PsaA purification process was similar to that described by Larentis et al. 2011 (Protein expression and Purification 78 (2011) 38). Purification was further optimized by mixed mode chromatography (Ceramic Hydroxyapatite Type-II) after DEAE to obtain PsaA of higher purity.
[0186] Anion Exchange Chromatography: XK16 / 20 column was filled with 30 ml of DEAE-Gel (GE) resin. The resin was washed with 5 column volumes of sterile distilled water and then with 10 column volumes of 20 mM Tris, 1 mM EDTA, pH 8.0 (equilibration buffer). 30 mL of supernatant was diluted to 100 mL with equilibration buffer and loaded onto the column and the flow through was collected. The column was washed with 5 volumes of equilibration buffer. PsaA was eluted with 12 volumes of linear gradient (0-100% B). (Buffer A contained 20 mM Tris, 1 mM EDTA pH 8.0; Buffer B - 20 mM Tris, 1 mM EDTA, 250 mM NaCl pH 8.0) and then the column was washed with 20 mM Tris, 1 mM EDTA, 1 mM NaCl pH 8.0.
[0187] Mixed Mode Chromatography: 25 ml of Ceramic Hydroxyapatite Type II (CHT-II) was packed in the column. The resin was washed with a volume of sterile distilled water followed by 10 volumes of 20 mM Tris pH 6.8. The eluted fractions from the DEAE resin were pooled and loaded onto the CHT-II resin, which showed a clear major visible band of PsaA at a good concentration of about 37 KD on SDS-PAGE. The flow-through was collected and the column was washed with 5 column volumes of equilibration buffer. The protein was eluted with a gradient of (15% B, 20% B, 50% B and 100% B) over 5 column volumes. Buffer A contained 20 mM Tris, pH 6.8, while buffer B contained 250 mM phosphate buffer, pH 6.8.
[0188] All eluted fractions showing a clean band of the expected PsaA size were pooled, concentrated using a 10 kDa MWCO cassette, and ultrafiltered against 20 mM phosphate buffer, pH 7.5. The purified protein was loaded on an SDS-PAGE gel for purity assessment.
[0189] B) Activation and conjugation of pneumococcal polysaccharide serotype 3 to PsaA
[0190] Size-reduced polysaccharide of serotype 3 (at a concentration of 5 mg / mL) and 1.5 mL of CDAP (100 mg / mL in acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1:0.5 (PS:CDAP) and stirred for 1 minute. The pH of the polysaccharide solution was adjusted to 9.0 with 3.5 mL of 0.2 M triethylamine and stirred at room temperature (RT) for 1 minute. 210 mg of PsaA (14.0 ml, at a concentration of 15.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1:0.7 (PnPs:PsaA).
[0191] The pH of the reaction was adjusted to about 9.01 with 0.7 mL of 0.2 M triethylamine and the reaction was stirred at room temperature for 5 hours, after which the reaction was quenched by adding excess glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Figure 1 A).
[0192] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0193] C) Activation and conjugation of pneumococcal polysaccharide serotype 6A to PsaA
[0194] Type 6A polysaccharide (at a concentration of 14.6 mg / mL) and 400 μL of CDAP (1100 mg / mL in acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1:1 (PS:CDAP) and stirred for 1 minute. The pH of the polysaccharide solution was adjusted to 9.0 with 800 μL of 0.2 M triethylamine and stirred at room temperature (RT) for 1 minute. 40 mg of PsaA (3.78 mL, at a concentration of 11.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1:1 (PnPs:PsaA).
[0195] The pH of the reaction was adjusted to about 9.01 with 0.7 mL of 0.2 M triethylamine, the reaction was stirred at room temperature for 5 hours, and then the reaction was quenched by adding excess glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Figure 2 B).
[0196] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0197] D) Activation and conjugation of pneumococcal polysaccharide serotype 6B to PsaA.
[0198] Size-reduced polysaccharide 6B (at a concentration of 14.97 mg / mL) and 4.0 mL of CDAP (100 mg / mL acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1:2 (PS:CDAP) and stirred for 1 minute. The pH of the polysaccharide solution was adjusted to 9.1 with 8.0 mL of 0.2 M triethylamine and stirred for 1 minute at room temperature (RT). 340 mg of PsaA (22.66 mL, at a concentration of 15.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1:1.7 (PnPs:PsaA).
[0199] The pH of the reaction was adjusted to about 9.01 with 0.7 mL of 0.2 M triethylamine, the reaction was stirred at room temperature for 5 hours, and then the reaction was quenched by adding excess glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Figure 1 B).
[0200] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0201] E) Activation and conjugation of pneumococcal polysaccharide serotype 8 to PsaA.
[0202] 1000 mg (200.0 mL of 5.0 mg / mL concentration) of mechanically ground polysaccharide serotype 8 and 4.0 mL of CDAP (100 mg / mL acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:0.4 (PS:CDAP) and stirred for 1 minute. The pH of the polysaccharide solution was adjusted to 9.0 with 8.0 ml of 0.2 M triethylamine and stirred at room temperature (RT) for 1 minute. 800 mg of PsaA (53.33 mL of 15.0 mg / mL concentration) was slowly added to the activated polysaccharide at a ratio of 1.0:0.8 (PnPs:PsaA).
[0203] The pH of the reaction was adjusted to 9.0 with 0.1 mL of 0.2 M triethylamine, and the reaction was stirred at room temperature for 3-5 hours, and then quenched by adding excess glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Figure 3 B).
[0204] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0205] F) Activation and conjugation of pneumococcal polysaccharide serotype 10A to PsaA.
[0206] 1000 mg (142.8 mL, 7.0 mg / mL) of mechanically ground polysaccharide serotype 10A and 6.0 mL of LCDAP (100 mg / mL (w / v) in acetonitrile) were mixed in a glass bottle and stirred for 1 min. The pH of the polysaccharide solution was adjusted to 9.0 with 8.0 mL of 0.2 M triethylamine and stirred for 1 min at room temperature (RT). 800 mg of PsaA (53.33 mL, 15.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1.0:0.8 (PnPs:PsaA).
[0207] The pH of the reaction was adjusted to 9.0 with 1.3 mL of 0.2 M triethylamine, the reaction was stirred at room temperature for 3-5 hours, and then the reaction was quenched by adding excess glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Figure 4 B).
[0208] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0209] G) Activation and conjugation of pneumococcal polysaccharide serotype 11A to PsaA.
[0210] 1000 mg (100.0 mL, 10.0 mg / mL) of mechanically ground polysaccharide serotype 11A and 8.0 mL of CDAP (100 mg / mL, w / v in acetonitrile) were mixed in a glass bottle at a ratio of 1.0:0.8 (PS:CDAP) and stirred for 1 min. The pH of the polysaccharide solution was adjusted to 9.0 with 14.0 mL of 0.2 M triethylamine and stirred for 1 min at room temperature (RT). 800 mg of PsaA (53.3 mL, 15.0 mg / mL) was slowly added to the active polysaccharide at a ratio of 1.0:0.8 (PnPs:PsaA).
[0211] The pH of the reaction was adjusted to 9.0 with 1.1 mL of 0.2 M triethylamine, and the reaction was stirred at room temperature for 3-5 hours, and then quenched by adding excess glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Figure 5 B).
[0212] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0213] H) Activation and conjugation of pneumococcal polysaccharide serotype 12F to PsaA.
[0214] 1000 mg (142.8 mL, 7.0 mg / mL) of mechanically ground polysaccharide serotype 12F and 4.0 mL of CDAP (100 mg / mL, acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:0.4 (PS:CDAP) and stirred for 1 minute. The pH of the polysaccharide solution was adjusted to 9.0 with 9.0 mL of 0.2 M triethylamine and stirred for 1 minute at room temperature (RT). 700 mg of PsaA (46.6 mL, 15.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1.0:0.7 (PnPs:PsaA).
[0215] The pH of the reaction was adjusted to 9.0 with 1.7 mL of 0.2 M triethylamine and the reaction was stirred at room temperature for 3-5 hours, and then the reaction was quenched by adding excess glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Figure 6 B).
[0216] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0217] I) Activation and conjugation of pneumococcal polysaccharide serotype 15A to PsaA.
[0218] 1000 mg (71.4 mL, 14.0 mg / mL) of mechanically ground 15A polysaccharide and 10.0 mL of CDAP (100 mg / mL, acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:1.0 (PS:CDAP) and stirred for 1 min. The pH of the polysaccharide solution was adjusted to 9.0 with 20.5 mL of 0.2 M triethylamine and stirred for 1 min at room temperature (RT). 1000 mg of PsaA (66.6 mL, 15.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1.0:1.0 (PnPs:PsaA).
[0219] The pH of the reaction was adjusted to 9.0 with 0.9 mL of 0.2 M triethylamine and the reaction was stirred at room temperature for 3-5 hours, and then the reaction was quenched by adding excess glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Figure 7 B).
[0220] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0221] J) Activation and conjugation of pneumococcal polysaccharide serotype 23A to PsaA.
[0222] 1000 mg (83.3 mL, 12.0 mg / mL) of mechanically ground polysaccharide serotype 23A and 10.0 mL CDAP (100 mg / mL, acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:1.0 (PS:CDAP) and stirred for 1 min. The pH of the polysaccharide solution was adjusted to 9.0 with 20.3 mL of 0.2 M triethylamine and stirred for 1 min at room temperature (RT). 600 mg of PsaA (40.0 mL, 15.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1.0:0.6 (PnPs:PsaA).
[0223] The pH of the reaction was adjusted to 9.0 with 1.1 mL of 0.2 M triethylamine and the reaction was stirred at room temperature for 3-5 hours, and then the reaction was quenched by adding excess concentration of glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Figure 8 B).
[0224] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0225] K) Activation and conjugation of pneumococcal polysaccharide serotype 23B to PsaA.
[0226] 1000 mg (100.0 mL of 10.0 mg / mL concentration) of mechanically ground polysaccharide serotype 23B and 2.0 mL of CDAP (100 mg / mL acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:0.2 (PS:CDAP) and stirred for 1 minute. The pH of the polysaccharide solution was adjusted to 9.0 with 3.0 mL of 0.2 M triethylamine and stirred for 1 minute at room temperature (RT). 1000 mg of PsaA (66.6 mL of 15.0 mg / mL concentration) was slowly added to the activated polysaccharide at a ratio of 1.0:1.0 (PnPs:PsaA).
[0227] The pH of the reaction was adjusted to 9.0 with 2.4 mL of 0.2 M triethylamine and the reaction was stirred at room temperature for 3-5 hours, and then the reaction was quenched by adding excess concentration of glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Fig. 9 B).
[0228] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0229] L) Activation and conjugation of pneumococcal polysaccharide serotype 24F to PsaA.
[0230] 1000 mg (125.0 mL 8.0 mg / mL concentration) of mechanically ground polysaccharide serotype 24F and 3.0 mL CDAP (100 mg / mL acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:0.3 (PS:CDAP) and stirred for 1 minute. The pH of the polysaccharide solution was adjusted to 9.0 with 10.0 mL of 0.2 M triethylamine and stirred at room temperature (RT) for 1 min. 600 mg of PsaA (40.0 mL, concentration of 15.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1.0:0.6 (PnPs:PsaA).
[0231] The pH of the reaction was adjusted to 9.0 with 3.5 mL of 0.2 M triethylamine and the reaction was stirred at room temperature for 3-5 hours, and then the reaction was quenched by adding excess concentration of glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Fig.10 B).
[0232] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0233] M) Activation and conjugation of pneumococcal polysaccharide serotype 35B to PsaA.
[0234] 1000 mg (142.8 ml at a concentration of 7.0 mg / mL) of mechanically ground polysaccharide serotype 35B and 6.0 mL of CDAP (100 mg / mL acetonitrile (w / v)) were mixed in a glass bottle at a ratio of 1.0:0.6 (PS:CDAP) and stirred for 1 minute. The pH of the polysaccharide solution was adjusted to 9.0 with 7.0 ml of 0.2 M triethylamine and stirred at room temperature (RT) for 1 minute. 1000 mg of PsaA (66.6 mL, concentration 15.0 mg / mL) was slowly added to the activated polysaccharide at a ratio of 1.0:1.0 (PnPs:PsaA).
[0235] The pH of the reaction was adjusted to 9.0 with 2.2 mL of 0.2 M triethylamine and the reaction was stirred at room temperature for 3-5 hours, and then the reaction was quenched by adding excess concentration of glycine (100 mM). The conjugation kinetics of the reaction were monitored every hour using SEC-HPLC ( Fig.11 B).
[0236] The reaction mixture was ultrafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Each component was analyzed by SEC-MALLS and anthrone methods, and the fractions containing the conjugate were combined and filtered using a 0.2 μm sterile filter.
[0237] Example 3: 24-valent pneumococcal capsular polysaccharide-protein conjugated vaccine composition (Formulation I)
[0238] Pneumococcal polysaccharides from serotypes 1, 4, 5, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F, 2.2 μg each, and 4.4 μg of 24-valent conjugate vaccine of serotype 6B (0.5 mL) with approximately 35 μg of CRM 197 and pneumococcal polysaccharides from serotypes 3, 6A, 8, 10A, 11A, 12F, 15A, 23A, 23B, 24F, and 35B, 2.2 μg each, conjugated to about 25 μg of PsaA, prepared in 5 mM succinic acid and about 0.07% w / v polysorbate 20 by adding each conjugate sequentially to a mixing vessel. 0.5 mg Al 200 mg / mL equivalent to 0.5 mL per dose was added to the mixed solution. 3+ of aluminum phosphate gel. The pH of the formulation was adjusted to 6.0 using 1N hydrochloric acid under constant stirring. After mixing for 2 hours, the formulated mixture was aseptically filled into 3 mL sterile non-siliconized vials at a fill volume of 0.58 mL per vial, closed with sterile 13 mm rubber stoppers, and sealed with 13 mm sterile pink flip-top aluminum seals, and the filled vials were then optically inspected and labeled. Some vials were randomly selected from the batch for analysis of appearance, pH, osmolarity, total polymer and protein content (μg / SHD), adsorption %, aluminum content (mg / SHD) (single dose in humans).
[0239] Table I: Characterization of Formulation (I)
[0240]
[0241]
[0242] Example 4: 24-valent pneumococcal capsular polysaccharide-protein conjugated vaccine composition (Formulation II)
[0243] Pneumococcal polysaccharides from serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, 2.2 μg each, and 4.4 μg of 24-valent conjugate vaccine of serotype 6B (0.5 mL) with 60 μg of CRM 197The conjugates were prepared in 5 mM succinic acid and approximately 0.07% w / v polysorbate 20 by adding each conjugate sequentially to a mixing vessel. To the mixed solution was added 0.5 mg Al 3+ of aluminum phosphate gel. The pH of the formulation was adjusted to 6.0 using 1N hydrochloric acid under constant stirring. After mixing for 2 hours, the formulated mixture was aseptically filled into 3 mL sterile non-siliconized vials at a fill volume of 0.58 mL per vial, closed with sterile 13 mm rubber stoppers, and sealed with 13 mm sterile pink flip-top aluminum seals, and the filled vials were then optically inspected and labeled. Some vials were randomly selected from the batch for analysis of appearance, pH, osmolarity, total polymer and protein content (μg / SHD), adsorption %, aluminum content (mg / SHD) (single dose in humans).
[0244] Table II: Characterization of Formulation (II)
[0245]
[0246]
[0247]
[0248] Example 5: Immune response of rabbits immunized with two conjugate vaccines carrying different carrier proteins
[0249] To evaluate immunogenicity, rabbits were immunized with formulations I and II. The study design included two groups of 7 rabbits each. Animals were immunized with three doses of each formulation. The blood collection and immunization schedule and grouping details are shown in the table below:
[0250] Table III: Evaluation of the immune response of rabbits to conventional and reduced antigen preparations
[0251]
[0252] Sera from immunized rabbits were collected at regular intervals. Serotype-specific IgG titers were assessed in an ELISA adapted from the WHO-recommended ELISA for assessing serum antibody titers in human sera. Antibody titers were assessed as OD above the cut-off value. 450nm The maximum serum dilution with the value of IgG titer was calculated using the IgG titer values of the animals before immunization. The GMFR titer values were plotted in the graph ( Fig. 12A and 12B ).
[0253] Titer was estimated as ELISA OD 450nm (optical density at 450 nm) above the critical value (2×OD observed in pre-immune serum450nm , OD value is about 0.1. ) The geometric mean doubling rate (GMFR) of each serotype is plotted. Sera obtained after 3 doses of immunization (after the third dose) were used to evaluate immunogenicity. The solid black bar indicates the difference with CRM 197 conjugated pneumococcal polysaccharide, while the colored bar represents pneumococcal polysaccharide conjugated to PsaA.
[0254] Serum IgG titers were found to be very similar in rabbits vaccinated with PCV24 (formulation I) or PCV24 (formulation II). GMFR responses except for serotypes 23A and 23B were slightly lower in the formulation I immunized group compared to formulation II. Most importantly, all rabbits vaccinated with a carrier protein (CRM 197 ; Formulation II) or two carrier proteins (CRM 197 All rabbits immunized with polysorbate containing 100% polysorbate (+PsaA; Formulation I) increased GMFR more than fourfold. A four-fold increase in antibody concentration is the acceptance criterion set by the WHO for pneumococcal vaccines. Therefore, this study shows that the presence of another carrier protein does not negatively affect the immune response of the vaccine formulation.
[0255] The present invention is not intended to be exhaustive or limit the present technology to the precise form disclosed herein. Although specific embodiments are disclosed herein for illustrative purposes, as will be appreciated by those of ordinary skill in the relevant art, various equivalent modifications are possible without departing from the present technology. In some cases, well-known structures and functions are not shown and / or described in detail to avoid unnecessarily obscuring the description of the embodiments of the present technology. Although the steps of the method may be presented in a particular order herein, in alternative embodiments, these steps may have another appropriate order. Similarly, certain embodiments of the present technology disclosed in the context of a particular embodiment may be combined or eliminated in other embodiments. In addition, although the advantages associated with certain embodiments may be disclosed in the context of these embodiments, other embodiments may also exhibit these advantages, and not all embodiments need to exhibit these advantages or other advantages disclosed herein to fall within the scope of the present technology. Therefore, the present invention and related technologies may include other embodiments that are not explicitly shown and / or described herein.
[0256] From the foregoing it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the scope of the invention.
[0257] Invention Advantages
[0258] The multivalent pneumococcal conjugate vaccine composition of the present invention provides a better immune response than the original multivalent pneumococcal vaccine and the existing pneumococcal conjugate vaccines.
Claims
1. A 24-valent pneumococcal conjugate vaccine composition comprising a 24-valent pneumococcal conjugate vaccine from Streptococcus pneumoniae ( Streptococcus pneumoniae ) serotype, wherein the serotype comprises 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B; The polysaccharides from each serotype are conjugated to a single 197 Carrier protein; in, Capsular polysaccharides and CRMs from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F, and 35B 197 conjugation; or, Capsular polysaccharides and CRMs from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F 197 Conjugation, capsular polysaccharides from serotypes 3, 6A, 8, 10A, 11A, 12F, 15A, 23A, 23B, 24F and 35B were conjugated to PsaA.
2. The 24-valent pneumococcal conjugate vaccine composition according to claim 1, It is characterized in that One or more pneumococcal polysaccharides are fragmented, and the average molecular weight of each fragmented pneumococcal polysaccharide is less than the average molecular weight of native pneumococcal polysaccharide and is in the range of 50-1000 kDa.
3. The 24-valent pneumococcal conjugate vaccine composition according to claim 2, It is characterized in that The pneumococcal polysaccharide has a molecular weight of 100-1000 kDa.
4. The 24-valent pneumococcal conjugate vaccine composition according to claim 2, It is characterized in that The pneumococcal polysaccharide has a molecular weight of 200-800 kDa.
5. The 24-valent pneumococcal conjugate vaccine composition according to claim 2, It is characterized in that The pneumococcal polysaccharide has a molecular weight of 250-600 kDa.
6. The 24-valent pneumococcal conjugate vaccine composition according to claim 2, It is characterized in that The pneumococcal polysaccharide has a molecular weight of 300-400 kDa.
7. The 24-valent pneumococcal conjugate vaccine composition according to claim 2, It is characterized in that The pneumococcal polysaccharide has a molecular weight of 70-150 kDa.
8. The 24-valent pneumococcal conjugate vaccine composition according to claim 2, It is characterized in that The pneumococcal polysaccharide has a molecular weight of 75-125 kDa.
9. The 24-valent pneumococcal conjugate vaccine composition according to claim 2, It is characterized in that The molecular weight of polysaccharide-protein conjugates is between 500 kDa and 5000 kDa.
10. The 24-valent pneumococcal conjugate vaccine composition according to claim 2, It is characterized in that The molecular weight of the polysaccharide-protein conjugate is between 1000 kDa and 10000 kDa.
11. The 24-valent pneumococcal conjugate vaccine composition according to claim 2, It is characterized in that The molecular weight of polysaccharide-protein conjugates is between 1500 kDa and 15000 kDa.
12. The 24-valent pneumococcal conjugate vaccine composition according to claim 2, It is characterized in that The molecular weight of polysaccharide-protein conjugates is between 2000 kDa and 20000 kDa.
13. The 24-valent pneumococcal conjugate vaccine composition according to claim 2, It is characterized in that The molecular weight of polysaccharide-protein conjugates is between 2500 kDa and 25000 kDa.
14. The 24-valent pneumococcal conjugate vaccine composition according to claim 2, It is characterized in that The molecular weight of polysaccharide-protein conjugates is between 3000 kDa and 30000 kDa.
15. The 24-valent pneumococcal conjugate vaccine composition according to claim 1, It is characterized in that The vaccine composition contains 2.2 μg of Streptococcus pneumoniae (S Treptococcus pneumoniae ) each capsular polysaccharide of serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, and 4.4 µg of polysaccharide from serotype 6B, wherein each capsular polysaccharide from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F is combined with 25-40 µg of CRM 197 The carrier protein was conjugated, and each capsular polysaccharide from serotypes 3, 6A, 8, 10A, 11A, 12F, 15A, 23A, 23B, 24F, and 35B was conjugated to 25-40 µg of PsaA.
16. The 24-valent pneumococcal conjugate vaccine composition according to claim 1, It is characterized in that The vaccine composition comprises 2.2-2.4 μg of each capsular polysaccharide of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, and 4.4 μg of capsular polysaccharide of Streptococcus pneumoniae serotype 6B, wherein each capsular polysaccharide is combined with 40-80 μg of CRM 197 Conjugation.
17. The pneumococcal conjugate vaccine composition according to claim 15 or 16, It is characterized in that The glycerol content of the capsular polysaccharide of Streptococcus pneumoniae serotype 15A is in the range of 5-18%.
18. The pneumococcal conjugate vaccine composition according to claim 15 or 16, It is characterized in that The acetate content of the capsular polysaccharide of Streptococcus pneumoniae serotype 35B is in the range of 2-10%.
19. The pneumococcal conjugate vaccine composition of claim 18, It is characterized in that The acetate content of the capsular polysaccharide of Streptococcus pneumoniae serotype 35B is 2-8%.
20. The 24-valent pneumococcal conjugate vaccine composition of claim 1, further comprising one or more of the following: a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant and / or a lyophilization excipient.
21. The 24-valent pneumococcal conjugate vaccine composition according to claim 20, It is characterized in that The adjuvant is aluminum phosphate.
22. The 24-valent pneumococcal conjugate vaccine composition according to claim 1, It is characterized in that Each dose of the vaccine composition comprises 0.1 μg-50 μg, 0.1 μg-10 μg, or 1 μg-5 μg of each pneumococcal polysaccharide conjugated to 1.5 μg-70 μg of each carrier protein.
23. The 24-valent pneumococcal conjugate vaccine composition according to claim 22, It is characterized in that Each pneumococcal polysaccharide in each dose of the vaccine composition is conjugated to 1.5 μg-5 μg of each carrier protein.
24. The 24-valent pneumococcal conjugate vaccine composition according to claim 1, It is characterized in that The percentage ratio of protein to polysaccharide (protein / PS) is 0.3-2.
0.
25. The 24-valent pneumococcal conjugate vaccine composition according to claim 24, It is characterized in that The percentage ratio of protein to polysaccharide (protein / PS) is 0.5-1.5 protein / PS.
26. The 24-valent pneumococcal conjugate vaccine composition according to claim 1, It is characterized in that The vaccine is formulated as a unit-dose vial, multi-dose vial, or pre-filled syringe.
27. The 24-valent pneumococcal conjugate vaccine composition according to claim 1, It is characterized in that The vaccine further comprises one or more preservatives selected from thimerosal and 2-phenoxyethanol, and the amount of the preservatives ranges from 4 mg / mL to 20 mg / mL.
28. The 24-valent pneumococcal conjugate vaccine composition according to claim 1, It is characterized in that The vaccine composition comprises CRM 197 Conjugated pneumococcal capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 14, 18C, 19A, 19F, 23F, 11A, 12F, 15A, 22F, 23A, 23B, 24F, 33F and 35B, wherein the composition has a pH of 4-7 and comprises: 4.4 μg / 0.5 mL of pneumococcal capsular polysaccharides from serotype 6B; 2.2-4 μg / 0.5 mL of pneumococcal capsular polysaccharides from all other serotypes; 40-80 μg / 0.5 mL of CRM 197 ; 0.2-2 mg / 0.5 mL aluminum phosphate; 1-10 mM succinate buffer; 0.5-2.5% w / v sodium chloride; 0.002-0.2% w / v polysorbate 80; and 4 mg / mL or 10 mg / 0.5 mL 2-phenoxyethanol.
29. The 24-valent pneumococcal conjugate vaccine composition according to claim 1, It is characterized in that The vaccine composition comprises CRM 197 Pneumococcal capsular polysaccharides from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F conjugated and PsaA conjugated to PsaA from serotypes 3, 6A, 8, 10A, 11A, 12F, 15A, 23A, 23B, 24F and 35B, wherein the composition has a pH of 4-7 and comprises: 4.4 μg / 0.5 mL of pneumococcal capsular polysaccharides from serotype 6B; 2.2-4 μg / 0.5 mL of pneumococcal capsular polysaccharides from all other serotypes; 20-40 μg / 0.5 mL of CRM 197 ; 20-40 μg / 0.5 mL of PsaA; 0.2-2 mg / 0.5 mL of aluminum phosphate; 1-10 mM succinate buffer; 0.5-2.5% w / v sodium chloride; 0.002-0.2% w / v polysorbate 80; and 4 mg / mL or 10 mg / 0.5 mL of 2-phenoxyethanol.
30. The 24-valent pneumococcal conjugate vaccine composition according to any one of the preceding claims is used in the preparation of a vaccine composition for preventing or treating Streptococcus pneumoniae ( Streptococcus pneumoniae )-mediated diseases.
31. The use according to claim 30, It is characterized in that The disease is invasive pneumococcal disease (IPD).
32. The use according to claim 31, It is characterized in that The subject is a human.
33. The use according to claim 32, It is characterized in that The subject is an infant less than 1 year old, a toddler between 12 months and 24 months old, a child between 2 years and 5 years old, an older child between 5 years and 13 years old, a teenager between 13 years and 18 years old, an adult between 18 years and 65 years old, or a senior citizen over 65 years old.
34. The use of claim 32, comprising administering the pneumococcal conjugate vaccine composition to a subject parenterally or mucosally.
35. The use according to claim 34, It is characterized in that The parenteral route is subcutaneous, intramuscular, intradermal and / or intravenous; The mucosal route is oral and / or nasal.
36. A method for preparing the 24-valent pneumococcal conjugate vaccine composition of claim 1, It is characterized in that The method comprises the following steps: (a) conjugating one or more of the 24 activated pneumococcal polysaccharides to an immunogenic carrier protein selected from a group consisting of PsaA and CRM 197 Group, (b) filtering and purifying the conjugate using size exclusion chromatography, (c) analyzing the purified fractions using SEC-MALLS, pooling the fractions containing each of the 24 conjugates, and filter-sterilizing the fractions containing the monovalent conjugate, and (d) formulating the 24 conjugates obtained in step (c), an adjuvant, one or more excipients and a buffer to prepare a 24-valent pneumococcal polysaccharide-protein conjugate composition.
Citation Information
Patent Citations
High-efficiency 14-valent pneumococcal conjugate vaccine
CN101590224A
Multivalent pneumococcus capsular polysaccharide-protein conjugated composition and preparation method thereof
CN103623401A
Multivalent pneumococcus capsular polysaccharide-protein conjugated composition and preparation method thereof
CN104069488A
Pneumococcal polysaccharide conjugate vaccine
US20100074922A1
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
US20100239604A1
